I am an associate professor in the department of Microbiology-Infectiology and Immunology, at the Laval University School of Medicine, and a member of the Infectious Diseases and Immunology Axis of the CHUQ Research Center, CHUL Pavilion.

I did my PhD at McGill University in molecular genetics and my post-doctoral studies at Thomas Jefferson University (Philadelphia) in cancer, during which I cloned two new genes that code for C-type lectin receptors. During my subsequent post-doctoral work at Laval University, my research focused on neutrophil biology, and specifically on signaling. The current research in my laboratory brings together these three fields of research, namely, genetics, C-type lectin receptors, and innate immunity.

The overall goal of the research in my laboratory is to further our understanding of the immunopathogenesis of two types of arthritis, namely rheumatoid arthritis and gout. Arthritis refers to a group of diseases that affect the joints and cause pain and inflammation. There are over 100 types of arthritis. Although drugs are available to treat different types of arthritis, many medications are associated with secondary side effects, and some patients don’t respond to available drugs. To address this unmet need, we must gain more insight into the pathogenesis of these diseases to develop more effective and less toxic drugs.

Our research revealed that the C-type lectin receptor known as Clec12A is involved in the pathogenesis of rheumatoid arthritis and gout. This discovery provides insight into one of the mechanisms through which the immune system is deregulated in these diseases. Clec12A is an inhibitory receptor that is expressed by the innate immune cells of the myeloid lineage, such as neutrophils and monocytes. It is also expressed by dendritic cells. Our current working hypothesis is that in gout and rheumatoid arthritis, the Clec12A inhibitory pathway is not fully functional, causing myeloid cells to be more easily activated.

We use a multidisciplinary approach to gain insight into how Clec12A works to determine its contribution to the pathogenesis of arthritis, with the goal of eventually transferring our findings to clinical practice. The molecular and cellular biology tools we use will shed light on how Cle12A dampens the activation of immune cells. To complement this line of research, the more clinical aspect of our Clec12A project involves the analysis of patient samples to better understand the potential role of this inhibitor in chronic inflammatory diseases (e.g.: gout and rheumatoid arthritis).

Another aspect of our research involves the development of a new anti-inflammatory drug to treat gout, using a rational drug design approach. This new drug may also have the ability to dampen inflammation in patients suffering from other inflammatory diseases.

In summary, our research aims to further our understanding of the pathogenesis of gout and rheumatoid arthritis, identify biomarkers for these diseases, as well as develop a new anti-inflammatory drug that is less toxic and more potent than those used to currently treat gout and other chronic inflammatory diseases. The results of this research will also shed light on the role of Clec12A in other chronic inflammatory diseases, since the Clec12A pathways also seem to be dysregulated in Crohn’s disease.

CHUL
2705, boulevard Laurier
T-1-49
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

35 entries « 1 of 7 »

Fernandes MJ, Naccache PH

The Role of Inhibitory Receptors in Monosodium Urate Crystal-Induced Inflammation.

Journal Article

Front Immunol, 9 , pp. 1883, 2018, ISSN: 1664-3224.

Abstract | Links:

Rousseau LS, Pare G, Lachhab A, Naccache PH, Marceau F, Tessier P, Pelletier M, Fernandes M

S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals.

Journal Article

J Leukoc Biol, 102 (3), pp. 805-813, 2017, ISSN: 0741-5400.

Abstract | Links:

Redelinghuys P, Whitehead L, Augello A, Drummond RA, Levesque JM, Vautier S, Reid DM, Kerscher B, Taylor JA, Nigrovic PA, Wright J, Murray GI, Willment JA, Hocking LJ, Fernandes MJ, De Bari C, Mcinnes IB, Brown GD

MICL controls inflammation in rheumatoid arthritis.

Journal Article

Ann Rheum Dis, 75 (7), pp. 1386-91, 2016, ISSN: 0003-4967.

Abstract | Links:

Naccache P, Fernandes MJ

Challenges in the characterization of neutrophil extracellular traps: The truth is in the details.

Journal Article

Eur J Immunol, 46 (1), pp. 52-5, 2016, ISSN: 0014-2980.

Abstract | Links:

Zhao C, Sardella A, Davis L, Poubelle PE, Bourgoin SG, Fernandes MJ

A transgenic mouse model for the in vivo bioluminescence imaging of the expression of the lysophosphatidic acid receptor 3: relevance for inflammation and uterine physiology research.

Journal Article

Transgenic Res, 24 (4), pp. 625-34, 2015, ISSN: 0962-8819.

Abstract | Links:

35 entries « 1 of 7 »

Active projects

  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Evaluation of low density neutrophils as biomarkers of lung function and disease progression in cystic fibrosis, Subvention, Rare Disease Foundation, Microgrant program, from 2018-02-27 to 2019-02-26
  • The characterization of MICL, a novel negative regulator of the immune response in arthritis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30

Recently finished projects

  • MICL : A novel negative regulator of Arthritis, Subvention, La société d'arthrite, Bourse de chercheur, from 2012-07-01 to 2016-06-30
  • Neutrophil 2018, Subvention, Instituts de recherche en santé du Canada, Subventions de planification et dissémination – Programme d’appui communautaire des instituts, from 2017-11-01 to 2018-10-31
  • Recherche sur une nouvelle drogue anti-inflammatoire, Subvention, Fondation du CHU de Québec, from 2016-12-19 to 2017-03-31
  • Unravelling the genetic basis of a novel, rare autoinflammatory disease: the potential role of a Clec12A genetic variant, Subvention, Rare Disease Foundation, Microgrant program, from 2016-07-01 to 2017-06-30
Data provided by the Université Laval research projects registery